Patent intelligence · CN
CN 115348859
Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate
Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrat…
Patent details — CN 115348859
- Jurisdiction
- CN
- Status
- granted
- Grant date
- Nov 15, 2022
- Expiration
- Nov 10, 2042
- Applicant
- BAYER HEALTHCARE AG
- CPC classes
- A61K 9/ 00 A I, A61K 47/ 10 A I, A61K 47/ 38 A I, A61K/31426
Quick answer
CN 115348859 (Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate) is held by BAYER HEALTHCARE AG. Status: granted. Granted Nov 15, 2022. Expires Nov 10, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAYER HEALTHCARE AG
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 47/ 10 A I, A61K 47/ 38 A I, A61K/31426, A61K/314439, A61K/4710
More from BAYER HEALTHCARE AG
Related pharmaceutical patents in our USPTO index.
-
WO 2024052517
USAGE MÉDICAL D'ANTICORPS ANTI-CCR8 ET PROGRAMME DE DOSAGE
granted -
CN 117186084
Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus
granted -
CN 115003329
Parapoxvirus for conditioning and treating coronavirus infections
granted -
BR 112021015776
Edição de gene para hemofilia a com expressão de fator viii melhorada
granted -
WO 2021152186
ANTICORPS CCR8 POUR APPLICATIONS THÉRAPEUTIQUES
granted -
DE 102019218587
Kontrastmittelbasierte Gefäßdarstellung
granted -
DE 102019218589
Simultane Bilddarstellung von zwei unterschiedlichen funktionellen Bereichen
granted
Frequently asked questions
What is US patent 115348859?
CN 115348859 (Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate) is held by BAYER HEALTHCARE AG. Status: granted. Granted Nov 15, 2022. Expires Nov 10, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CN 115348859?
BAYER HEALTHCARE AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does CN 115348859 expire?
Our index shows an expiration date of Nov 10, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.